Fragile X syndrome (FXS) is an inherited form of intellectual disability that is usually caused by expansion of a polymorphic CGG repeat in the 5 ′ untranslated region of the X-linked FMR1 gene, which leads to hypermethylation and transcriptional silencing. Two non-neurological phenotypes of FXS are enlarged testes and connective tissue dysplasia, which could be caused by alterations in a growth factor signaling pathway. FXS patients also frequently have autistic-like symptoms, suggesting that the signaling pathways affected in FXS may overlap with those affected in autism. Identifying these pathways is important for both understanding the effects of FMR1 inactivation and developing treatments for both FXS and autism. Here we show that decreasing the levels of the insulin-like growth factor (Igf) receptor 1 corrects a number of phenotypes in the mouse model of FXS, including macro-orchidism, and that increasing the levels of IGF2 exacerbates the seizure susceptibility phenotype. These results suggest that the pathways altered by the loss of the FMR1-encoded protein (FMRP) may overlap with the pathways affected by changes in Igf signaling or that one or more of the proteins that play a role in Igf signaling could interact with FMRP. They also indicate a new set of potential targets for drug treatment of FXS and autism spectrum disorders.
Fragile X syndrome (FXS) is an inherited form of intellectual disability that affects about 1 in 5000 males. It is usually caused by expansion of an unstable CGG repeat in the 5 ′ untranslated region of the X-linked FMR1 gene, which leads to hypermethylation and transcriptional silencing (Coffee et al. 2009 ). The other phenotypes of FXS include neurons with immature and dense dendritic spines, enlarged testes (macro-orchidism), some subtle features related to connective tissue dysplasia, accelerated prepubescent growth and increased susceptibility to seizures (Garber et al. 2008) . Fragile X syndrome patients also frequently have autistic-like symptoms, including hand flapping, hand biting and gaze avoidance (Harris et al. 2008) . This suggests that there may be some mechanistic connection between the effects of the FMR1 mutation and the causes of autism. For instance, the signaling pathways affected in FXS may overlap with those affected in autism. Identifying these pathways is important for both understanding the effects of FMR1 inactivation and developing treatments for both FXS and autism.
Most evidence indicates that FMRP is a selective RNA-binding protein that acts as a translational repressor (Ashley et al. 1993; Laggerbauer et al. 2001) . To explain the increase in synaptic long-term depression in the hippocampus of Fmr1 knockout (KO) mice, it has been proposed that FMRP normally regulates translation of mRNAs that are activated by metabotropic glutamate receptors (mGluRs) in the dendrites (Huber et al. 2002) . There is good evidence supporting this hypothesis: some of the phenotypes of Fmr1 KO mice can be corrected by administration of mGluR antagonists (Michalon et al. 2012; Yan et al. 2005) or by producing Fmr1 KO mice that are heterozygous for a Grm5 KO (Dolen et al. 2007) . It has been reported that stimulation of mGluR5 activates the PI3K/AKT/mTOR signaling pathway and that there are small increases in the activities of several proteins in this pathway in Fmr1 KO mice and FXS patients (Gross et al. 2015; Hoeffer et al. 2012; Sharma et al. 2010) . This is also the primary signaling pathway activated by the insulin-like growth factors 1 and 2 (IGF1, IGF2) (LeRoith et al. 1995) . Both of these embryonic growth factors signal by binding to the insulin-like growth factor receptor 1 (IGF1R), the insulin receptor (IR) and IGF1R/IR hybrid receptors at the cell surface; their effects are also mediated by the Igf2 receptor and the Igf binding proteins. It has also been reported that stimulation of mGlur5 activates the MAPK kinase ERK1/2 signaling pathway (Ferraguti et al. 1999; Hou & Klann 2004; Osterweil et al. 2010) ; stimulation of the IGF1R by Igfs also activates the ERK1/2 signaling pathway (LeRoith 2000) . This overlap in signaling pathways used by the mGLUR5 and the IGF1R suggests that decreasing the levels of IGF1R might dampen the effects of mGLUR5 activation on unregulated translation in the Fmr1 KO mice (Fig. 1) .
There is considerable evidence that Igf signaling plays a role in testis development, Male mice homozygous for a mutation in the Igf1 gene are infertile dwarfs (Baker et al. 1996) and male mice that are triply homozygous mutant for Igf1r, Ir and insulin-related receptor (Irr) are completely sex-reversed and express only female-specific markers (Nef et al. 2003) . Igf signaling is also known to play an important role in ovarian follicular development and function (Kwintkiewicz & Giudice 2009 ). These reports suggest that increased Igf signaling could play a role in both the enlarged testis and ovary phenotypes of Fmr1 KO mice (Ascano et al. 2012; The Dutch-Belgian Fragile X Consortium 1994) . We hypothesized, therefore, that decreasing the levels of IGF1R would decrease the size of the testes in Fmr1 KO mice by decreasing their response to IGF1 and/or IGFII.
Igf signaling also plays a role in neuron function. Overexpression of Igf1 in the brain promotes both neurogenesis and synaptogenesis (O'Kusky et al. 2000) . Igf signaling also plays a role in ocular dominance plasticity in the visual cortex (Tropea et al. 2006) , axon guidance in the olfactory bulb (Scolnick et al. 2008) , memory consolidation (Chen et al. 2011) , modulating sensory experience in the visual cortex (Mardinly et al. 2016) , and regulating presynaptic transmission in the hippocampus (Gazit et al. 2016) . It is possible therefore, that there is perturbed Igf signaling in the brains of Fmr1 KO mice that could be related to Igf signaling changes in the testes. If this is the case, then reducing IGF1R levels might correct some of the behavioral phenotypes seen in Fmr1 KO mice. Here we show that decreasing the levels of IGF1R corrects a number of phenotypes in Fmr1 KO mice. 
Materials and methods

Mice
Audiogenic seizure test
This test was done as described (Yan et al. 2005) on mice that were 23-26 days old during the light phase. The mice were acclimated to the chamber for 2 min and the exposed to a Streetwise personal alarm (>124 decibels) for 5 min. We recorded as positive mice that had either clonic/tonic or status epilepticus seizures. All mice were tested blind to the genotype.
Open field test
Ten-week-old mice were placed in a 40 × 40 cm 2 plexiglass box during the light phase and the distance traveled for 30 min was measured with a video camera using Anymaze software (v. 4.99). The time spent grooming and rearing on their hind legs was recorded by the experimenter. All mice were tested blind to the genotype.
Analysis of testis weight
The wet weight of testes was measured blind to the genotype.
Western blot analysis
Acid extraction of proteins from mouse tissues for IGF1 and IGF2 analysis by Western blotting was done as described (Pravtcheva & Wise 2008) , to dissociate IGF1 and IGF2 from tightly bound IGF binding proteins. The Igf1 antibody was from Sigma (St. Louis, MO, US) (SAB2501424); this antibody does not recognize the mature form of IGF1 because it was made from a peptide just outside of mature protein sequence. The Igf2 antibody (S1F2) and the HMGB1 antibody (07-584) were from EMD-Millipore (Billerica, MA, US); HMGB1 was used as a loading control for protein extracts prepared under acidic conditions. For analysis of all other proteins, tissues were homogenized on ice using a dounce homogenizer in RIPA buffer with protease and phosphatase inhibitors (Sigma), the homogenate was spun at 10 000 g for 10 min at 4 ∘ C, and protein concentrations were measured on the supernatant with the BCA method (Pierce). Samples were heated at 95 ∘ C in Laemmli loading buffer, resolved on SDS polyacrylamide gels and transferred to PVDF membranes. After incubation with the primary antibody, immunoblots were incubated with alkaline phosphatase-conjugated secondary antibody and developed with CDP-star. Igf1r (9750), AKT (4691), p(T308)AKT (9275), ERK1/2 (9102) and p(Ty202/204)ERK1/2 (4370) antibodies were from Cell Signaling, Actin antibody was from Sigma (A2066). Dr. Richard Kascsak supplied FMRP antibody 5C2.
DNA analysis
DNA was extracted from tails and genotyped by PCR as described (Holzenberger et al. 2000; Wise & Pravatcheva 1997 , The Jackson Laboratory genotyping protocol was used for Fmr1 tm1Cg PCR.
Statistical analysis
All statistics were performed with Graphpad Prism (v. 4) and Sigmaplot (v. 11.0) software. Data were analyzed for normality by the 
Results
Because several of the phenotypes in FXS suggest that there may be increased Igf signaling (enlarged testes, accelerated prepubescent growth, increased PI3K/AKT/mTOR signaling) we first determined if introduction of an Igf1r KO mutation into Fmr1 KO mice would rescue their susceptibility to AGS. Mice heterozygous for Igf1r KO mutation will have a 50% reduction in IGF1R levels and are slightly smaller (Holzenberger et al. 2000) , mice that are homozygous for the Igf1r KO die at birth from respiratory failure (Liu et al. 1993) . This reduction in IGF1R levels in turn leads to reduced phosphorylation of AKT and ERK1/2 in response to stimulation by IGF1 (Holzenberger et al. 2003) . We used Igf1r KO mice (originally created on a 129/SV background) that have been backcrossed with FVB/N mice for >11 generations to create a congenic line. We crossed these heterozygous Igf1r KO mice with Fmr1 KO mice that were on an FVB/N background (which lose most of their vision at around 4 weeks of age) or with Fmr1 KO mice on an FVB/N background with vision restored (homozygous for the wild-type pdeB6 and tyrosinase c-ch genes; Irwin et al. 2002) . We examined all four possible genotypes from these crosses: Fmr1 KO only, FVB/N (with or without vision) only, Igf1r KO only, or Fmr1 KO/Igf1r KO. The results (Tables 1 and 2) show that there are significant differences in AGS susceptibility between the Fmr1 -/y mice and the Igf1r +/− /Fmr1 -/y mice on both strain backgrounds (Fisher's exact test Fmr1 -/y :Igf1r +/− /Fmr1 -/y , P < 0.0001 [FVB/N background]; Fmr1 -/y :Igf1r +/− /Fmr1 -/y , P = 0.001 [FVB/N background with vision]). The incidence of seizures was reduced from 90% to 25% in the presence of the Igf1r KO on the FVB/N background and from 59% to 8% on the FVB/N background with vision. This is an almost complete rescue of the phenotype and was greater than the effect of a KO mutation in the mGlur5 (Grm5) gene (reduced from 72% to 33%), although the Grm5 KO experiments were done on a different genetic background (C57Bl/6; Dolen et al. 2007) . The difference between Fmr1 KO seizure incidence on the strains with and without vision was not quite significant (P = 0.051, Fisher's exact test). The mice without vision have been backcrossed against the FVB/N strain for many more generations (>34, Carl Dobkin, personal communication) than the mice with vision (11, The Jackson Laboratory), so there may be other differences between these strains in addition to their differences in vision.
Because the Igf1r KO was correcting the AGS phenotype, increased Igf signaling may play a role in the seizure susceptibility phenotype. We hypothesized, therefore, that overexpression of IGF1 or IGF2 would have the opposite effect and exacerbate this phenotype, To test this hypothesis the Fmr1 KO mice were crossed with mice that are hemizygous for an Igf2 transgene regulated by the H19 enhancers. This transgene is expressed in a number of tissues, including the brain, and causes metastasizing mammary adenocarcinomas in females (Pravtcheva & Wise 1998; Wise & Pravatcheva 1997) . We noticed that mice with both the Fmr1 KO and the Igf2 transgene were developing seizures very rapidly after exposure to the stimulus and therefore measured the latency time to onset of seizures. We found that Fmr1 -/y /Igf2+ mice had a significantly shortened the latency time to the onset of seizures (Kaplan Meier analysis, P = 0.0013) (Fig. 2, Table 3 ). The H19 enhancers-Igf2 transgenic mice were also more susceptible than FVB/N mice to AGS (P = 0.0281). These results are consistent with previous observations that Igf2 KO mice are more resistant to kainic acid-induced seizures (Dikkes et al. 2007 There were no significant differences between the Fmr1 KO mice and the FVB/N mice in the time spent grooming or time spent rearing (not shown). Introduction of the Igf1r KO corrected the hyperactivity phenotype as measured by total distance traveled, average speed and time immobile (Fig  3a-d) , because the Igf1r +/− /Fmr1 -/y mice did not significantly differ from the FVB/N or Igf1r +/− mice in each test when analyzed by Student's t-test (Fig. 3b,d ,e). The Igf1r KO did not significantly alter the time spent in the center of the field (Fig. 3h) . Two-way ANOVA with one repeated measure indicated that there were significant differences between all four groups in distance traveled, average speed, time immobile and time in center when analyzed in 60 second time segments (Fig. 3a,c = 4.09, P = 0.010). One-way ANOVA indicated that there were also significant differences between all four groups in total distance traveled, average speed, time immobile and time in center (Fig. 3b,d ,f,h): Distance traveled, F 3,57 = 4.69, P = 0.005; Average speed, F 3,57 = 4.70, P = 0.005; Time immobile, F 3,57 = 5.10, P = 0.003, Time in center, F 3,57 = 4.09, P = 0.010). These results should be interpreted with some caution because differences between the Fmr1 KO and FVB/N mice were small and we did not correct for multiple comparisons. We then examined the effect of the Igf1r KO mutation on the macro-orchidism phenotype by measuring the wet weight of testes from 9-week-old male mice (Fig. 4) If FMRP was directly regulating levels of an Igf signaling protein by translational repression, then there should be increased levels of this protein in Fmr1 KO mice. We determined if there were any obvious changes in the levels of IGF1R, IGF1 or IGF2 in Fmr1 KO mice by Western blot analysis. We first examined the levels of IGF1R in total brain extracts from 8-day-old Fmr1 KO mice, because we would expect any effects of FMRP on IGF1R levels to act early in postnatal development. There were no significant differences between the levels of IGF1R in Fmr1 KO and FVB/N mice [t(4) = 1.31, P = 0.261; Fig. 5a ]. We also looked at the levels of IGF1 and IGF2 in extracts from the heads and livers of 17-day-old Fmr1 KO and FVB/N embryos, because Igf1 and Igf2 are most highly expressed in during embryonic development (Fig. 5b,c) . We also did not see any significant differences between the levels of either IGF1 or IGF2 in the heads or livers of these 17-day old Fmr1 KO and FVB/N embryos (IGF2/HMGB1: t(4) = 0.022, P = 0.983 and t(4) = 0.765, P = 0.487 for head and liver, respectively; IGF1/HMGB1: t(4) = 0.598, P = 0.582 and t(4) = 0.169, P = 0.874 for head and liver, respectively).
Because it has been reported that there are increased basal levels of phosphorylated AKT and ERK1/2 in the hippocampus and brain of Fmr1 KO mice (Deacon et al. 2015; Gross et al. 2010; Sharma et al. 2010) , we examined the levels of these proteins in total brain extracts from 8-day-old Fmr1 KO and Fmr1 KO/Igf1r KO mice by Western blot analysis (the Igf1r KO mice do not have changes in the basal levels of either pAKT or pERK1/2 (Holzenberger et al. 2003) (Biondi et al. 2015) ). We first confirmed that the Fmr1 KO mice do not express FMRP and that the levels of IGF1R are reduced by 50% in heterozygous Igf1r KO mice (Fig. 6a) . We did not, however, see any increase in the basal levels of either pAKT (Thr 308) [Student's t-test, t(4) = 2.03, P = 0.112] or pERK1/2 (Thr202/Tyr204) [t(4) = 0.307, P = 0.774] in the Fmr1 KO mice or any decrease in the basal levels of these proteins in the brains of Igf1r KO or the Igf1r +/− /Fmr1 -/y mice (Fig. 6b,c) (pAKT/AKT: ANOVA: F 3,8 = 2.571, P = 0.127: pERK/ERK: ANOVA: F 3,8 = 1.031, P = 0.956).
Discussion
Our results show that changes in Igf signaling have striking effects on several of the major phenotypes seen in Fmr1 KO mice, including macro-orchidism. Either FMRP is indeed regulating the levels of one or more of the Igf signaling proteins by translational repression or there is an indirect effect on one or more of the signaling pathways that are altered by the loss of FMRP. The results from our expression analysis suggest that FMRP is not repressing the levels of the Igf signaling proteins we looked at so far across a wide range of cell types in e17 and p8 brain or e17 liver, but do not rule out the possibility that FMRP is directly affecting the levels of these proteins in specific regions of the brain, specific cell types or during other times of development. We have yet to examine whether the Fmr1 KO affects expression of other proteins involved in Igf signaling, for instance the Igf binding proteins.
Igf1r is highly expressed in the choroid plexus epithelium at the blood-CSF interface, in brain vessels, and in the glial end-feet surrounding them, where it plays a role in transporting serum IGF1 into the brain (Nishijima et al. 2010) . Thus, loss of FMRP could change the pattern or expression levels of Igf1r specifically at the blood-brain barrier, leading to higher than normal levels of IGF1 or IGF2 or errant targeting of these growth factors to the wrong regions of the brain. Pertinently, failure of blood-brain barrier function has also been implicated in epilepsy (Oby & Janigro 2006; van Vliet et al. 2007 ). There is a structure similar to the blood-brain barrier in the testis, the blood-testis barrier (Mital et al. 2011) . Both Igf1 and Igf1r are also expressed in Sertoli cells of the testes (Villalpando et al. 2008) , which separate the germ cells from the blood supply, so an effect of FMRP loss on Igf signaling at the blood-testis barrier could also explain the macro-orchidism phenotype. Igf1r also has other roles in endothelial cells that could be relevant to FXS. For instance, it is a negative regulator of production of the antioxidant/anti-inflammatory signaling radical nitric oxide (Imrie et al. 2012) .
Our results also indicate that increased Igf signaling exacerbates the AGS phenotype in Fmr1 KO mice. These results are the opposite of the effects of increased Igf signaling (by treatment with des(1-3)Igf1) on Mecp2 KO (Rett syndrome) mice (Tropea et al. 2009 ), which results in the correction of a number of their abnormal phenotypes. Rett syndrome (RTT) is another X-linked neurological disease that usually affects females (Chahrour & Zoghbi 2007) . Mecp2 KO mice, however, have several phenotypes that are the opposite of Fmr1 KO mice, which could be due to decreased Igf signaling: undescended testes, uneven wearing of the teeth (we have observed overgrowth of the teeth in our H19 enhancers-Igf2 transgenic mice (Wise & Pravatcheva 1997) ), lower body and brain weight on some genetic backgrounds, and lower neuron spine density. It has also been shown that Igf binding protein 3 (IGFBP3), an inhibitor of IGF1 and IGF2 activity, is regulated by Mecp2 and elevated in the brains of Mecp2 KO mice and Rett syndrome patients (although changes in the levels of IGF1 in serum have not been seen). Thus, our results suggest that changes in Igf signaling can have very different effects on two autism spectrum disorders. Our results also suggest that IGF1R may be a possible drug target for treatment of FXS. IGF1R might be a good therapeutic target because disruption of its activity in the brain may not have such widespread consequences on normal processes as disruption of mGlur5, for instance. A disadvantage, however, is that an IGF1R inhibitor could not be used very early in development because it would inhibit normal growth.
We did not see any changes in the basal levels of two downstream signaling targets of both mGLUR5 and IGF1R, pAKT and pERK1/2, in the brains of either Fmr1 KO mice or Fmr1 KO/Igf1r KO mice. Osterweil et al. (2010) reported that there was no difference in the basal levels of either pAKT or pERK1/2 in hippocampal slices of Fmr1 KO mice, but did see increases in the levels of pERK1/2 after stimulation of mGLUR5 with DHPG. They suggested that different results reported by various labs could be due to differences in the source of tissue and how the protein extracts are prepared. The IGF1R reduction could also be affecting very rapid short-term changes in these pathways after stimulation at synapses that are difficult to detect. IGF1R also activates the JAK/STAT signaling pathway (Himpe & Kooijman 2009 ) so changes in this pathway could be playing a role in the correction of the Fmr1 KO phenotypes. We will need to do a more detailed examination of specific regions and cell types of the brain to get more insight into the effects of the Igf1r KO on these pathways.
IGF1R reduction could also be having an effect on the Fragile X phenotypes by reducing presynaptic neurotransmitter release and calcium influx (Gazit et al. 2016) , which are enhanced in hippocampal and cortical pyramidal neurons of Fmr1 KO mice (Deng et al. 2013) , or by reducing inhibitory synaptic inputs into neurons (Mardinly et al. 2016) , although there is currently little evidence for alterations in inhibitory neurons in Fmr1 KO mice (Contractor et al. 2015) .
It has been reported that a des(1-3) IGF1 analog, NNZ-2566, can correct a number of phenotypes in Fmr1 KO mice (Deacon et al. 2015) . This analog, however, has a number of effects that are not consistent with previously described effects of IGF1: decreased AKT and ERK signaling, decreased spine density and decreased testis size; and there is no biochemical evidence that it has IGF1 activity. Our results suggest that this analog could be acting as a competitive inhibitor of IGF1 or IGF2. It has also been reported that des(1-3) IGF1 may have a mode of action that is independent of the IGF1 receptor (Nilsson-Hakansson et al. 1993 ) and this may also be the case for NNZ-2566.
Our results may also have more general implications for possible causes of autism. It has been reported that obesity (and associated diabetes) in either the mother or the father can lead to an increased risk of autism, and autistic children also have an increased incidence of obesity (Broder-Fingert et al. 2014; Krakowiak et al. 2012; Suren et al. 2014) . Obese individuals have higher levels of free IGF1 and IGF2, and total IGF2 (Frystyk et al. 1999) . Thus the increased incidence of obesity could play some role in the increased incidence of autism. Head circumference and brain weight are also larger in a significant percentage of autistic children (Bauman et al. 1997; Bolton et al. 2001) ; this could also be due to overexpression of either IGF1 or IGF2. There have been conflicting reports of increased levels of both IGF1 and IGF2 in the serum and decreased levels of IGF1 in the cerebrospinal fluid (CSF) of autistic children (Mills et al. 2007; Vanhala et al. 2001) , but levels of IGFs in the serum and CSF may not correlate with those in the brain (particularly if autistic children had a defect at the blood-brain barrier). Our results suggest that IGF2 may play a more important role in altering the AGS phenotype (and possibly autism) than IGF1, since there have been no other reports of effects on this phenotype in Igf1 KO or transgenic mice (the levels of IGF2 in human serum are higher than the levels of IGF1 (Yu et al. 1999) ).
Further experiments with other Igf signaling KOs and transgenes will help us to clarify which of the Igf signaling proteins has the most important effects on the Fragile X phenotype and further expression analysis will indicate if any of the Igf signaling proteins are a direct target of FMRP in specific regions of the brain.
